Trial Profile
A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH23537 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs YH 23537 (Primary)
- Indications Periodontitis
- Focus Therapeutic Use
- Sponsors Yuhan
- 14 Jan 2019 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2016 New trial record